Tags

Type your tag names separated by a space and hit enter

Impact of Underlying Comorbidities on Mortality in SARS-COV-2 Infected Cancer Patients: A Systematic Review and Meta-Analysis.
Asian Pac J Cancer Prev. 2021 May 01; 22(5):1333-1349.AP

Abstract

BACKGROUND

The evidence has shown that SARS CoV-2 infected patients with comorbidities are more likely to have severe disease sequel and mortality. In SARS-CoV-2 infected cancer patients risks associated with other underlying comorbidities might vary from those in non-cancer SARS CoV-2 infected patients. The relative impact of different underlying health conditions among patients with cancer and SARS CoV-2 infection remains yet to be explored. This systematic review aims to explore the prevalence of comorbidities among cancer patients with SARS CoV-2 infection and their impact on mortality.

METHODS

Online databases PubMed, Embase, Scopus and Web of science were searched for articles published between 9th July 2019 to July 8th 2020.Studies of cancer patients (>18 years) with diagnosis of SARS CoV-2 infection, published in English were included. A random-effects modelling for the meta-analyses was applied to assess the pooled prevalence and odds ratio for mortality due to comorbidities in SARS CoV-2 infected cancer patients.

RESULTS

Total 31studies with 4086 SARS-CoV-2 infectedcancer patientsmet the inclusion criteria. Most prevalent co-morbidities in cancer patients with SARS CoV-2 infection were hypertension [42.3% (95%CI:37.5- 47.0)], diabetes [17.8% (95% CI: 15.3-20.4)] and cardiovascular diseases [16.7% (95%CI:12.9-20.4)].The risk of mortality (pOR) was significantly higher in individuals with hypertension[1.6(95%CI 1.24-2.00)], cardiovascular diseases [2.2 (95%CI 1.49- 3.27)], chronic obstructive pulmonary diseases [1.4(95% CI 1.05-2.00)] and diabetes [1.35(95%CI 1.06-1.73)].

CONCLUSION

Our results indicates that the mortality in SARS-CoV-2 infected cancer patients is affected by preexisting non-cancer comorbidities. By identifying the comorbidities predictive for mortality, clinicians can better stratify the risk of cancer patients presenting with SARS-COV-2, on their initial contact with health services.<br />.

Authors+Show Affiliations

Department of Community Medicine & School of Public Health, PGIMER, Chandigarh, India.Department of Community Medicine & School of Public Health, PGIMER, Chandigarh, India.Department of Community Medicine & School of Public Health, PGIMER, Chandigarh, India.Cancer Prevention and Control Program, Georgetown University School of Medicine, Georgetown University, Washington DC, USA.

Pub Type(s)

Journal Article
Meta-Analysis
Systematic Review

Language

eng

PubMed ID

34048161

Citation

Kaur, Harmanjeet, et al. "Impact of Underlying Comorbidities On Mortality in SARS-COV-2 Infected Cancer Patients: a Systematic Review and Meta-Analysis." Asian Pacific Journal of Cancer Prevention : APJCP, vol. 22, no. 5, 2021, pp. 1333-1349.
Kaur H, Thakur JS, Paika R, et al. Impact of Underlying Comorbidities on Mortality in SARS-COV-2 Infected Cancer Patients: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev. 2021;22(5):1333-1349.
Kaur, H., Thakur, J. S., Paika, R., & Advani, S. M. (2021). Impact of Underlying Comorbidities on Mortality in SARS-COV-2 Infected Cancer Patients: A Systematic Review and Meta-Analysis. Asian Pacific Journal of Cancer Prevention : APJCP, 22(5), 1333-1349. https://doi.org/10.31557/APJCP.2021.22.5.1333
Kaur H, et al. Impact of Underlying Comorbidities On Mortality in SARS-COV-2 Infected Cancer Patients: a Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev. 2021 May 1;22(5):1333-1349. PubMed PMID: 34048161.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of Underlying Comorbidities on Mortality in SARS-COV-2 Infected Cancer Patients: A Systematic Review and Meta-Analysis. AU - Kaur,Harmanjeet, AU - Thakur,J S, AU - Paika,Ronika, AU - Advani,Shailesh M, Y1 - 2021/05/01/ PY - 2020/10/07/received PY - 2021/5/28/entrez PY - 2021/5/29/pubmed PY - 2021/6/2/medline KW - COVID-19 KW - Carcinoma KW - Case fatality KW - Prevalence KW - review SP - 1333 EP - 1349 JF - Asian Pacific journal of cancer prevention : APJCP JO - Asian Pac J Cancer Prev VL - 22 IS - 5 N2 - BACKGROUND: The evidence has shown that SARS CoV-2 infected patients with comorbidities are more likely to have severe disease sequel and mortality. In SARS-CoV-2 infected cancer patients risks associated with other underlying comorbidities might vary from those in non-cancer SARS CoV-2 infected patients. The relative impact of different underlying health conditions among patients with cancer and SARS CoV-2 infection remains yet to be explored. This systematic review aims to explore the prevalence of comorbidities among cancer patients with SARS CoV-2 infection and their impact on mortality. METHODS: Online databases PubMed, Embase, Scopus and Web of science were searched for articles published between 9th July 2019 to July 8th 2020.Studies of cancer patients (>18 years) with diagnosis of SARS CoV-2 infection, published in English were included. A random-effects modelling for the meta-analyses was applied to assess the pooled prevalence and odds ratio for mortality due to comorbidities in SARS CoV-2 infected cancer patients. RESULTS: Total 31studies with 4086 SARS-CoV-2 infectedcancer patientsmet the inclusion criteria. Most prevalent co-morbidities in cancer patients with SARS CoV-2 infection were hypertension [42.3% (95%CI:37.5- 47.0)], diabetes [17.8% (95% CI: 15.3-20.4)] and cardiovascular diseases [16.7% (95%CI:12.9-20.4)].The risk of mortality (pOR) was significantly higher in individuals with hypertension[1.6(95%CI 1.24-2.00)], cardiovascular diseases [2.2 (95%CI 1.49- 3.27)], chronic obstructive pulmonary diseases [1.4(95% CI 1.05-2.00)] and diabetes [1.35(95%CI 1.06-1.73)]. CONCLUSION: Our results indicates that the mortality in SARS-CoV-2 infected cancer patients is affected by preexisting non-cancer comorbidities. By identifying the comorbidities predictive for mortality, clinicians can better stratify the risk of cancer patients presenting with SARS-COV-2, on their initial contact with health services.<br />. SN - 2476-762X UR - https://www.unboundmedicine.com/medline/citation/34048161/Impact_of_Underlying_Comorbidities_on_Mortality_in_SARS_COV_2_Infected_Cancer_Patients:_A_Systematic_Review_and_Meta_Analysis_ L2 - http://journal.waocp.org/?sid=Entrez:PubMed&amp;id=pmid:34048161&amp;key=2021.22.5.1333 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.